Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.
Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse ...
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March ...
Citing Neal’s Yard Remedies’ hair treatment as “great for managing symptoms,” Maguire enjoys how the included rosemary, ...
A mother-of-two claims to have found a "miracle" cure for her psoriasis almost three decades after first being diagnosed with ...
Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...
Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...
Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety ...
Journalist working with Al Jazeera killed in Israeli Gaza strike, network says Almirall, a global pharmaceutical company dedicated to medical dermatology hosts the 16 th edition of Skin Academy, a ...
Researchers from Anew Therapeutics Pte Ltd. recently detailed the discovery of novel oral IL-17A small-molecule inhibitors as candidates for the treatment of psoriasis.
In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...
Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback